Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive antibody combo targets thyroid cancer

NCT ID NCT00467506

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing a two-step radioimmunotherapy for people with medullary thyroid cancer that has come back. Participants receive a bispecific antibody followed by a radioactive peptide. The goal is to see if this targeted radiation can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a two-step radioimmunotherapy using a bispecific antibody and a radioactive peptide
What this could lead to
If it works, this approach could offer a way to deliver radiation directly to medullary thyroid cancer cells while sparing healthy tissue.
What could go wrong
This is a Phase II trial with a small number of participants, so results may not apply broadly. The treatment involves radiation and an experimental antibody, which carries risks of toxicity and may not control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Start date

May 2004

Finished

Jan 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 -75 years * Karnofsky ≥ 70% * Histological diagnosis of medullary thyroid carcinoma * Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years * Normal liver and renal functions * Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3 * No immunization * Consent form signed

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medullary thyroid carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial medullary thyroid carcinoma Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid neoplasms

Contacts and locations

Locations

  • CHU

    Lyon, 69394, France

  • CHU

    Nantes, 44093, France

  • CHU

    Rouen, 76230, France

  • CHU de Grenoble

    Grenoble, 38043, France

  • Centre Claudius Régaud

    Toulouse, 31052, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre René Gauducheau

    Saint-Herblain, 440805, France

  • Centre René Huguenin

    Saint-Cloud, 92210, France

  • Hôpital de la timone

    Marseille, 13385, France

  • hôpital du Cluzeau

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.